Section 1: The Rise and Fall of Sentiment
In this article, I’ll outline why I see $Hims & Hers Health Inc.(HIMS)$
To grasp the full scope of this opportunity, we have to look back to mid-Q4 2025. On October 15th, the company announced that its Hers brand would enter the menopause treatment market—a massive, underserved sector. Investors cheered, sending the stock soaring toward $65. At the height of the frenzy, CEO Andrew Dudum even fueled the fire by reposting a comment that read, “Let the short squeeze begin.”
However, that peak was short-lived. The following day, the stock slid 8%. Sentiment soured further when news broke that Dudum had sold a portion of his shares via a pre-planned sale, leading to another ~15% drop.
The Reality Check:
While the sale represented less than 1% of his total holdings, the optics were undeniably messy. Bragging about a short squeeze immediately before a sale damaged investor confidence. This lapse in judgment acted as the catalyst for a grueling six-month sell-off, compounded by intensifying regulatory scrutiny over GLP-1 drugs and a market-punished normalization of revenue growth.
--
Section 2: Regulatory Friction and Legal Escalation
The pressure intensified when Hims & Hers launched a compounded semaglutide pill. The FDA reacted aggressively, signaling a "crackdown" on unapproved compounded GLP-1 medications and specifically calling out $HIMS. The agency warned it would utilize its full enforcement toolkit—including seizures and injunctions—against firms marketing these unapproved alternatives.
Hims & Hers pivoted almost instantly, pulling the product just 24 hours later, but the market was unforgiving. The stock tumbled over 10% in after-hours trading.
The situation reached a breaking point the following Monday morning. Novo Nordisk initiated a lawsuit against $HIMS, aiming to permanently bar the company from selling compounded drugs that allegedly infringe on its patents, while also seeking financial damages.
--
Section 3: The Capitulation and the "Unimaginable" Pivot
Following the legal onslaught, the stock plummeted over 20% in a single session. Sentiment hit rock bottom as $HIMS traded at a forward EV/EBITDA multiple of approximately 14x—an 80% collapse from its highs. The market had effectively priced in a total business failure.
Then, just one month later, the narrative took a 180-degree turn. Novo Nordisk dropped its lawsuit and, in a shocking twist, formed a strategic partnership with $HIMS.
The Deal Structure:
Distribution: Novo Nordisk will distribute branded GLP-1s (Wegovy and Ozempic) via the Hims & Hers platform.
Concession: Hims agreed to stop advertising compounded GLP-1s, though it retained the right to provide them for medical necessity.
The Result: The stock skyrocketed over 40% in a single day.
While the price drifted slightly lower in the following weeks, the fundamental thesis improved: the litigation "overhang" was gone, and $HIMS was now a partner to a global pharma giant while trading at a still-reasonable ~17x forward EV/EBITDA.
--
Section 4: The Peptide Unlock – A Structural Shift
The next major catalyst is the FDA-driven "unlock" of peptides. Peptides are short amino acid chains that act as precise signaling molecules. While GLP-1s (like semaglutide) have already revolutionized obesity and cardiovascular care, they are just the tip of the iceberg. The broader landscape includes:
Hormone optimization and metabolic health.
Muscle recovery and cognitive performance.
Sleep regulation and anti-aging.
Until now, the bottleneck was regulation. In 2023, many promising compounds were placed on the FDA’s “Category 2” list, banning them from being compounded due to safety concerns. This didn't kill demand; it simply moved it to the gray market.
The RFK Jr. Catalyst:
Everything changed this week when U.S. Health Secretary Robert F. Kennedy Jr. signaled that 12 peptides would be removed from the restricted Category 2 list. This is not a minor tweak—it is a structural pivot. By legitimizing these compounds, the government is moving a niche, offshore market into the regulated, taxable healthcare system.
--
Section 5: The Infrastructure Advantage
When a category moves from "restricted" to "accessible," the bottleneck shifts from legality to supply. Not every telehealth platform or pharmacy is equipped to handle the manufacturing and distribution of complex, regulated peptide chains at scale.
This is where $HIMS pulls ahead. Unlike many competitors who are mere "demand aggregators," Hims & Hers has invested heavily in vertical integration. It is currently the only scaled telehealth platform with the infrastructure to manufacture peptides in-house.
In a world where supply becomes the ultimate constraint, being the producer—not just the middleman—is everything.
--
Section 6: Valuation and the Path to $40
Following the RFK Jr. comments, the stock surged nearly 50% in a week. As of April 17th, $HIMS trades at roughly 20x forward EV/EBITDA. While some worry the "easy money" has been made, the risk profile has changed:
Litigation risk is dead.
A Big Pharma partnership is live.
A massive new growth vector (peptides) is opening.
The Price Target:
I believe a fair value multiple is closer to 30x forward EV/EBITDA, implying a share price of roughly $40. While the "asymmetric" $20 entry point is gone, current estimates still don't account for the margin expansion potential of the peptide thesis or contributions from initiatives like Eucalyptus.
The M&A Wildcard:
Finally, $HIMS is a prime takeover candidate. With millions of active users and a built-in DTC distribution engine, it is an incredibly attractive target for a large pharmaceutical company or a healthcare giant looking to buy instant, scaled access to the modern consumer.
--
@TigerObserver @TigerClub @TigerStars @TigerPM @Daily_Discussion
Comments